Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1
Tihamer Orban, Jay M Sosenko, David Cuthbertson, Jeffrey P Krischer, Jay S Skyler, Richard Jackson, Liping Yu, Jerry P Palmer, Desmond Schatz, George Eisenbarth, Diabetes Prevention Trial-Type 1 Study Group, Tihamer Orban, Jay M Sosenko, David Cuthbertson, Jeffrey P Krischer, Jay S Skyler, Richard Jackson, Liping Yu, Jerry P Palmer, Desmond Schatz, George Eisenbarth, Diabetes Prevention Trial-Type 1 Study Group
Abstract
Objective: There is limited information from large-scale prospective studies regarding the prediction of type 1 diabetes by specific types of pancreatic islet autoantibodies, either alone or in combination. Thus, we studied the extent to which specific autoantibodies are predictive of type 1 diabetes.
Research design and methods: Two cohorts were derived from the first screening for islet cell autoantibodies (ICAs) in the Diabetes Prevention Trial-Type 1 (DPT-1). Autoantibodies to GAD 65 (GAD65), insulinoma-associated antigen-2 (ICA512), and insulin (micro-IAA [mIAA]) were also measured. Participants were followed for the occurrence of type 1 diabetes. One cohort (Questionnaire) included those who did not enter the DPT-1 trials, but responded to questionnaires (n = 28,507, 2.4% ICA(+)). The other cohort (Trials) included DPT-1 participants (n = 528, 83.3% ICA(+)).
Results: In both cohorts autoantibody number was highly predictive of type 1 diabetes (P < 0.001). The Questionnaire cohort was used to assess prediction according to the type of autoantibody. As single autoantibodies, ICA (3.9%), GAD65 (4.4%), and ICA512 (4.6%) were similarly predictive of type 1 diabetes in proportional hazards models (P < 0.001 for all). However, no subjects with mIAA as single autoantibodies developed type 1 diabetes. As second autoantibodies, all except mIAA added significantly (P < 0.001) to the prediction of type 1 diabetes. Within the positive range, GAD65 and ICA autoantibody titers were predictive of type 1 diabetes.
Conclusions: The data indicate that the number of autoantibodies is predictive of type 1 diabetes. However, mIAA is less predictive of type 1 diabetes than other autoantibodies. Autoantibody number, type of autoantibody, and autoantibody titer must be carefully considered in planning prevention trials for type 1 diabetes.
Figures
References
- Bottazzo GF, Florin-Christensen A, Doniach D: Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279– 1282
- Lendrum R, Walker G, Cudworth AG, Theophanides C, Pyke DA, Bloom A, Gamble DR: Islet-cell antibodies in diabetes mellitus. Lancet 1976; 2: 1273– 1276
- Gorsuch AN, Spencer KM, Lister J, McNally JM, Dean BM, Bottazzo GF, Cudworth AG: Evidence for a long prediabetic period in type I (insulin dependent) diabetes mellitus. Lancet 1981; 2: 1363– 1365
- Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL: Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337– 1339
- Wilkin T, Hoskins PJ, Armitage M, Rodier M, Casey C, Diaz JL, Pyke DA, Leslie RD: Value of insulin autoantibodies as serum markers for insulin-dependent diabetes mellitus. Lancet 1985; 480– 481
- Baekkeskov S, Landin M, Kristensen JK, Srikanta S, Bruining GJ, Mandrup-Poulsen T, de Beaufort C, Soeldner JS, Eisenbarth G, Lindgren F: Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. J Clin Invest 1987; 79: 926– 934
- Christie MR, Vohra G, Champagne P, Daneman D, Delovitch TL: Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. J Exp Med 1990; 172: 789– 794
- Payton MA, Hawkes CJ, Christie MR: Relationship of 37,000 and 40,000-Mr tryptic fragment of islet antigens in insulin dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA 512). J Clin Invest 1995; 96: 1506– 1511
- Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase HP, Eisenbarth GS: Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996; 9: 379– 383
- Kulmala P, Savola K, Petersen JS, Vahasalo P, Karjalainen J, Lopponen T, Dyrberg T, Akerblom HK, Knip M: Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes: a population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 1998; 101: 327– 336
- Achenbach P, Bonifacio E, Williams AJK, Ziegler AG, Gale EAM, Bingley PJ. ENDIT Group. Autoantibodies to IA-2β improve diabetes risk assessment in high-risk relatives. Diabetologia 2008; 51: 488– 492
- Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pfluger M, Illig T, Bonifacio E, Ziegler A-G: Autoantibodies to zinc transporter 8 and SLC3018 genotype stratify type 1 diabetes risk. Diabetologia 2009; 52: 1881– 1888
- Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L, Karlsen AE, Boel E, Michelsen B, Lernmark A: A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37: 344– 350
- Diabetes Prevention Trial–Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 1685– 1691
- Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E: Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial–Type 1. Diabetes Care 2005; 28: 1068– 1076
- Bingley PJ, Gale EAM. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006; 49: 881– 890
- Krischer JP, Cuthbertson DD, Liping Yu, Orban Tihamer, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS: Screening strategies for identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 103– 108
- Bottazzo GF, Gleichmann H: Immunology and Diabetes Workshops: report of the First International Workshop on Standardization of Cytoplasmic Islet Cell Antibodies. Diabetologia 1986; 29: 125– 126
- Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P, Klingensmith G, Erlich H, Norris J, Eisenbarth GS: Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 1996; 81: 4264– 4267
- Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA: A novel micro-assay for insulin autoantibodies. J Autoimmun 1997; 10: 473– 478
- Greenbaum CJ, Sears KL, Kahn SE, Palmer JP: Relationship of β-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study. Diabetes 1999; 48: 170– 175
- Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA: Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994; 43: 1304– 1310
- Bingley PJ. for the ICARUS Group. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives. Diabetes 1996; 45: 1720– 1728
- Pitropaolo M, Libman IM, Pietropaolo SL, Riley K, LaPorte RE, Drash AL, Mazumdar S, Trucco M, Becker DJ: Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies. Pediatr Diabetes 2005; 6: 181– 183
- Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJK, Bingley PJ, Bonifacio E, Ziegler A-G: Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004; 53: 384– 392
- Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler A-G, Bonifacio E: Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004; 114: 589– 597
Source: PubMed